Routine Magnesium Replacement in the ICU: Challenging the Dogma of Tachyarrhythmia Prevention

Highlights

• Magnesium supplementation for patients with serum levels near institutional cutoffs was not associated with a reduction in tachyarrhythmias within 24 hours.
• The study utilized a fuzzy regression discontinuity design, a robust quasi-experimental method, to minimize confounding by indication across 93 ICUs.
• No significant differences were observed in secondary outcomes, including the incidence of hypotension or all-cause mortality.
• Findings remained consistent across various treatment thresholds, ranging from 1.6 mg/dL to 2.0 mg/dL.

The Clinical Ritual of Electrolyte Correction

In the high-acuity environment of the Intensive Care Unit (ICU), the correction of serum electrolytes is a daily, often hourly, ritual. Magnesium, the second most abundant intracellular cation, is frequently at the center of this practice. Clinicians have long maintained a low threshold for magnesium supplementation, driven by the physiological understanding that hypomagnesemia can predispose the myocardium to electrical instability. This practice is particularly prevalent in the prevention of supraventricular and ventricular tachyarrhythmias, most notably atrial fibrillation.

Despite its ubiquity, the evidence base for magnesium replacement in non-cardiac surgery ICU patients is surprisingly thin. Most protocols are derived from small-scale studies in post-cardiac surgery populations or extrapolated from acute myocardial infarction data from decades ago. Traditional observational studies on this topic are notoriously difficult to interpret due to ‘confounding by indication’—the very patients who receive magnesium are often those at higher baseline risk for arrhythmias. Consequently, a critical question remains: does the routine administration of magnesium to patients with borderline low levels actually improve clinical outcomes?

Study Design: The Power of Fuzzy Regression Discontinuity

To address this gap, Goulden and colleagues conducted a sophisticated nonrandomized clinical trial using data from 93 ICUs across the United States and Europe between 2003 and 2022. Recognizing that a traditional randomized controlled trial (RCT) of this scale would be logistically and financially daunting, the researchers employed a fuzzy regression discontinuity design.

This quasi-experimental approach exploits the fact that clinical decisions are often dictated by arbitrary thresholds. In many ICUs, a serum magnesium level of 1.8 mg/dL might trigger a supplement order, while 1.9 mg/dL does not. By comparing patients who fall just below the cutoff (and thus receive the intervention) with those who fall just above it (and do not), researchers can approximate the conditions of a randomized trial. This method effectively isolates the causal effect of the treatment from the underlying clinical status of the patient.

The study analyzed 478,901 twenty-four-hour treatment windows from 171,727 ICU admissions. The cohort was diverse, with a mean age of 63 years and a slight male predominance (57.6%). The primary endpoint was the occurrence of any ventricular or supraventricular tachyarrhythmia within 24 hours of testing. Secondary endpoints included episodes of hypotension and death.

Key Findings: A Consistent Lack of Benefit

The results of the analysis were strikingly uniform. Across all evaluated treatment cutoffs (1.6 mg/dL to 2.0 mg/dL), there was no evidence that magnesium supplementation influenced the risk of tachyarrhythmia. The risk difference was a negligible 0.1% (95% CI, -4.2 to 6.9). In clinical terms, this suggests that the intervention provided no measurable protection against rhythmic instability for patients near the threshold.

Furthermore, the study examined whether supplementation might impact other markers of clinical stability. The occurrence of hypotension showed no significant association with magnesium administration (risk difference, 1.2%; 95% CI, -0.9 to 17.7). Perhaps most importantly, there was no observed benefit regarding mortality, with a risk difference of 1.4% (95% CI, -0.6 to 5.3). These findings suggest that the common practice of ‘topping off’ magnesium levels does not alter the short-term trajectory of critically ill patients.

Expert Commentary: Methodological Strengths and Practical Implications

The strength of this study lies in its scale and its innovative methodology. By leveraging a fuzzy regression discontinuity design, the authors bypassed the inherent biases that plague standard observational datasets. The inclusion of nearly 100 ICUs over a two-decade span ensures that the findings are representative of a wide range of clinical practices and patient populations.

However, it is important to contextualize these findings within the broader landscape of critical care. The study specifically looked at patients near institutional cutoffs—the ‘borderline’ cases. It does not necessarily negate the need for magnesium replacement in cases of profound hypomagnesemia (e.g., <1.0 mg/dL) or in specific clinical scenarios such as torsades de pointes, pre-eclampsia, or severe asthma exacerbations.

From a health policy and resource utilization perspective, these results are significant. Magnesium supplementation is not a ‘free’ intervention. It requires nursing time for administration, pharmacy resources for preparation, and repeated blood draws for monitoring. In an era where ‘choosing wisely’ and reducing low-value care are priorities, the routine correction of mild hypomagnesemia may be an area ripe for protocol de-implementation. Clinicians may need to shift from a reflexive response to laboratory values toward a more nuanced, patient-specific approach.

Conclusion: Reassessing Routine Practice

The study by Goulden et al. provides high-quality evidence that the routine administration of magnesium to ICU patients with serum levels near standard treatment thresholds does not prevent tachyarrhythmias, hypotension, or death. While magnesium remains a vital tool in specific emergencies, its role as a prophylactic agent for borderline levels appears overstated.

These findings should encourage critical care committees to re-evaluate their electrolyte replacement protocols. By reducing unnecessary supplementation, healthcare systems can decrease nursing workload and focus resources on interventions with a more robust evidence base. Future research should perhaps focus on identifying the specific sub-populations—if any—that truly benefit from aggressive magnesium management, rather than applying a broad-brush approach to all critically ill patients.

References

1. Goulden R, Abrahamowicz M, Strumpf E, Tamblyn R. Magnesium Supplementation and Tachyarrhythmias: A Nonrandomized Clinical Trial. JAMA Intern Med. 2025 Dec 8:e256572. doi: 10.1001/jamainternmed.2025.6572.
2. Cook RC, Humphries KH, Gin K, et al. Prophylactic magnesium does not prevent atrial fibrillation after cardiac surgery: a meta-analysis. Ann Thorac Surg. 2013;95(2):533-541.
3. Tong GM, Rude RK. Magnesium deficiency in critical illness. J Intensive Care Med. 2005;20(1):3-17.